{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:57:37Z","timestamp":1785484657605,"version":"3.56.0"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271498"],"award-info":[{"award-number":["82271498"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341246"],"award-info":[{"award-number":["82341246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473766"],"award-info":[{"award-number":["82473766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Status epilepticus (SE), a life-threatening neurological emergency, is primarily treated with benzodiazepines (BZDs), which act as positive allosteric modulators (PAMs) of \u03b32-containing GABAA receptors (GABAARs). However, their efficacy diminishes due to \u03b32 subunit internalization, leading to pharmaco-resistance. In this manuscript, a series of 2-(2-thienyl)-thiazolo[4,5-d]pyrimidin-7(6H)-one derivatives were designed and evaluated using two-electrode voltage clamp in Xenopus oocytes expressing \u03b11\u03b22 GABAARs. We identified (S)-9d as a potent \u03b11\u03b22\u03b32 subtype PAM, showing 13-fold potentiation at 10 \u03bcM (EC50: 0.9 \u03bcM in oocytes, 0.2 \u03bcM in CHO cells) as well as \u03b11\u03b22 (EC50 = 1.3 \u03bcM, 1700% enhancement, in oocytes). Molecular docking and mutagenesis revealed (S)-9d binds to a distinct \u03b2+\/\u03b1\u2013 interface of \u03b11\u03b22 GABAARs. In SE mouse models, (S)-9d (5\u201330 mg\/kg) significantly suppressed seizure progression and reduced delayed mortality, outperforming diazepam. This study establishes a promising strategy for refractory SE to overcome BZD limitations.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c00903","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:54:41Z","timestamp":1752162881000},"page":"15910-15932","source":"Crossref","is-referenced-by-count":1,"title":["Novel 2-(2-Thienyl)-thiazolo[4,5-\n                    <i>d<\/i>\n                    ]pyrimidin-7(6\n                    <i>H<\/i>\n                    )-ones Binding \u03b2+\/\u03b1\u2013\nSubunit Interface as GABAAR Positive Allosteric Modulator\nfor the Treatment of Status Epilepticus in Mouse"],"prefix":"10.1021","volume":"68","author":[{"given":"Weiming","family":"Liao","sequence":"first","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]},{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhe","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]},{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-9497","authenticated-orcid":true,"given":"Liangren","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-5877","authenticated-orcid":true,"given":"Qi","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9198-4778","authenticated-orcid":true,"given":"Zhuo","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]},{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2026073103022202600_cit1","doi-asserted-by":"crossref","unstructured":"Proposal for revised\nclinical and electroencephalographic classification of epileptic seizures.\nFrom the commission on classification and terminology of the international\nleague against epilepsy\n          Epilepsia\n          1981; Vol. 22(4), , pp 489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"issue":"4","key":"2026073103022202600_cit2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1212\/WNL.46.4.1029","article-title":"A prospective,\npopulation-based epidemiologic study of status epilepticus in Richmond,\nVirginia","volume":"46","author":"DeLorenzo","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"2026073103022202600_cit3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status\nepilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol."},{"key":"2026073103022202600_cit4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1528-1167.2005.00409.x","article-title":"Mortality after a first\nepisode of status epilepticus in the United States and Europe","volume":"46","author":"Logroscino","year":"2005","journal-title":"Epilepsia"},{"key":"2026073103022202600_cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.109050","article-title":"Has the mortality\nof status epilepticus changed over\nthe past few decades?","volume":"138","author":"Neligan","year":"2023","journal-title":"Epilepsy Behav."},{"key":"2026073103022202600_cit6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/OAEM.S293258","article-title":"Optimal management\nof status epilepticus\nin children in the emergency setting: A review of recent advances","volume":"14","author":"Messahel","year":"2022","journal-title":"Open\nAccess Emerg. Med."},{"issue":"2","key":"2026073103022202600_cit7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/WCO.0000000000000899","article-title":"Update on the management of status epilepticus","volume":"34","author":"Rossetti","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"2026073103022202600_cit8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5090074","article-title":"Adult status epilepticus: A review\nof the prehospital and emergency eepartment management","volume":"5","author":"Billington","year":"2016","journal-title":"J. Clin. Med."},{"issue":"7824","key":"2026073103022202600_cit9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics\nand benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"issue":"10","key":"2026073103022202600_cit10","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.3426-07.2008","article-title":"Subunit-specific\ntrafficking of GABA(A) receptors during status epilepticus","volume":"28","author":"Goodkin","year":"2008","journal-title":"J. Neurosci."},{"issue":"1","key":"2026073103022202600_cit11","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABAA receptors: structure, function, pharmacology,\nand related disorders","volume":"19","author":"Ghit","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"1","key":"2026073103022202600_cit12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based\nguideline: Treatment of convulsive status epilepticus in children\nand adults: report of the guideline committee of the American epilepsy\nsociety","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr."},{"issue":"3","key":"2026073103022202600_cit13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive\ntherapy\nin super-refractory status epilepticus","volume":"82","author":"Rosenthal","year":"2017","journal-title":"Ann.\nNeurol."},{"issue":"0 6","key":"2026073103022202600_cit14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"issue":"9","key":"2026073103022202600_cit15","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/epi.17343","article-title":"Intravenous ganaxolone for the treatment of refractory\nstatus epilepticus: Results from an open-label, dose-finding, phase\n2 trial","volume":"63","author":"Vaitkevicius","year":"2022","journal-title":"Epilepsia"},{"issue":"2","key":"2026073103022202600_cit16","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12996","article-title":"Allopregnanolone:\nAn overview on its synthesis and effects","volume":"34","author":"Diviccaro","year":"2022","journal-title":"J.\nNeuroendocrinol."},{"issue":"1","key":"2026073103022202600_cit17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1474-4422(24)00430-7","article-title":"Diagnosis and management of status epilepticus: improving\nthe status quo","volume":"24","author":"Gettings","year":"2025","journal-title":"Lancet Neurol."},{"key":"2026073103022202600_cit18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.36255\/exon-publications-epilepsy-status-epilepticus","article-title":"Modern Treatment\nof Status Epilepticus in Adults","volume-title":"Epilepsy","author":"Heuser","year":"2022"},{"issue":"1","key":"2026073103022202600_cit19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00134-023-07263-w","article-title":"Status epilepticus\nin the ICU","volume":"50","author":"Rossetti","year":"2024","journal-title":"Intensive Care Med."},{"issue":"11","key":"2026073103022202600_cit20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamaneurol.2023.3542","article-title":"Efficacy and safety of XEN1101, a novel potassium channel opener,\nin adults with focal epilepsy: A phase 2b randomized clinical trial","volume":"80","author":"French","year":"2023","journal-title":"JAMA Neurol."},{"issue":"11","key":"2026073103022202600_cit21","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/acn3.50896","article-title":"TMS as a pharmacodynamic indicator\nof cortical activity\nof a novel anti-epileptic drug, XEN1101","volume":"6","author":"Premoli","year":"2019","journal-title":"Ann.\nClin. Transl. Neurol."},{"issue":"1","key":"2026073103022202600_cit22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1021\/acs.jmedchem.7b01492","article-title":"Design and\nsynthesis of novel positive allosteric modulators of \u03b17 nicotinic\nacetylcholine receptors with the ability to rescue auditory gating\ndeficit in mice","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"issue":"16","key":"2026073103022202600_cit23","doi-asserted-by":"publisher","first-page":"12379","DOI":"10.1021\/acs.jmedchem.1c01058","article-title":"Synthesis\nand biological evaluation of novel triazine derivatives\nas positive allosteric modulators of \u03b17 nicotinic acetylcholine\nreceptors","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026073103022202600_cit24","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1021\/acs.jmedchem.3c02323","article-title":"Allosteric activation\nof \u03b17 nicotinic acetylcholine receptors by novel 2-arylamino-thiazole-5-carboxylic\nacid amide derivatives for the improvement of cognitive deficits in\nmice","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026073103022202600_cit25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk9484","article-title":"Termination\nof convulsion\nseizures by destabilizing and perturbing seizure memory engrams","volume":"10","author":"Lai","year":"2024","journal-title":"Sci. Adv."},{"issue":"29","key":"2026073103022202600_cit26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400560","article-title":"A novel ubiquitin ligase adaptor\nPTPRN suppresses seizure susceptibility through endocytosis of Na(V)1.2\nsodium channels","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"issue":"1","key":"2026073103022202600_cit27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bph.17360","article-title":"Carvedilol\ninhibits neuronal hyperexcitability\ncaused by epilepsy-associated KCNT1 mutations","volume":"182","author":"Di","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"2026073103022202600_cit28","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87559","article-title":"Coupling of slack and Na(V)1.6 sensitizes slack to quinidine blockade\nand guides anti-seizure strategy development","volume":"12","author":"Yuan","year":"2024","journal-title":"eLife"},{"issue":"33","key":"2026073103022202600_cit29","doi-asserted-by":"publisher","first-page":"27378","DOI":"10.1039\/C6RA00855K","article-title":"Deep eutectic solvent mediated synthesis of quinazolinones\nand dihydroquinazolinones: synthesis of natural products and drugs","volume":"6","author":"Ghosh","year":"2016","journal-title":"RSC Adv."},{"issue":"2","key":"2026073103022202600_cit30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1124\/mol.115.099291","article-title":"A multifaceted GABAA\nreceptor modulator: Functional properties and mechanism of action\nof the sedative-hypnotic and recreational drug methaqualone (quaalude)","volume":"88","author":"Hammer","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"7740","key":"2026073103022202600_cit31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","article-title":"GABA(A) receptor signalling mechanisms\nrevealed by structural pharmacology","volume":"565","author":"Masiulis","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026073103022202600_cit32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing\nactions of neurosteroids on GABA(A) receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"2026073103022202600_cit33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06361-4","article-title":"Structural\nbasis of neurosteroid anesthetic action\non GABA(A) receptors","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"2026073103022202600_cit34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49471-y","article-title":"Structural\ninsights into GABA(A) receptor potentiation by quaalude","volume":"15","author":"Chojnacka","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"2026073103022202600_cit35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205717","article-title":"Characterization\nof a Novel Repeat-dosing Model for Preclinical Diazepam Studies (P1\u20134.001)","volume":"102","author":"Guignet","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"2026073103022202600_cit36","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1021\/acs.jnatprod.1c00840","article-title":"Clerodane diterpenes from casearia\ncorymbosa as allosteric GABAA receptor modulators","volume":"85","author":"Syafni","year":"2022","journal-title":"J. Nat. Prod."},{"key":"2026073103022202600_cit37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuroscience.2011.03.066","article-title":"Psychotropic and nonpsychotropic\ncannabis derivatives inhibit human 5-HT3A receptors through a receptor\ndesensitization-dependent mechanism","volume":"184","author":"Xiong","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"2026073103022202600_cit38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete\nstructure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"issue":"1","key":"2026073103022202600_cit39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal\nstructure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr.,\nSect. C:Struct. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c00903","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/15910\/66298120\/acs.jmedchem.5c00903.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/15910\/66298120\/acs.jmedchem.5c00903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:02:34Z","timestamp":1785481354000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/15\/15910\/5234958\/Novel-2-2-Thienyl-thiazolo-4-5-d-pyrimidin-7-6H"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":39,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,7,10]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00903","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}